In conclusion, HIV-associated malignancies represent a significant health challenge for PLWH. Elucidating the underlying mechanisms and identifying biomarkers using oncogenic proteomics approaches are critical steps toward translating research findings into clinical applications. By leveraging the power of proteomics, we can pave the way for more targeted and personalized interventions in the prevention, diagnosis, and treatment of HIV-associated malignancies. Advances in oncogenic proteomics hold great promise for understanding the molecular mechanisms underlying HIV-associated malignancies. By unravelling the complex interactions between HIV, viral coinfections, immune dysfunction, and tumorigenesis, proteomic approaches can facilitate the development of novel diagnostic tools, therapeutic strategies, and personalized treatments. Continued research efforts in this field will aid in improving patient outcomes and reducing the burden of HIV-associated malignancies worldwide.